Focus Stocks
A 52 Week High for Biogen Idec, will it Hold?
Published on Wednesday, 04 April 2012 11:34 Written by TradersHuddle Wire
New York, April 4th (TradersHuddle.com) - Shares of Biogen Idec Inc. (NASDAQ:BIIB) booked a new 52 week high today by trading above $128.87, traders are definitely monitoring Biogen's price action to see if this move attracts further buying into the stock.
Biogen Idec Inc. (NASDAQ:BIIB) develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The products from the biotechnology company addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis. The company was founded in 1985 and is based in
Biogen Idec is currently trading 0.36% versus its previous trading session close, and it has calculated support and resistance at $116.44 and $127.85 respectively. Clearly, with this action this range has been penetrated, and traders will be reviewing price action to establish a new tradable range.
The overall market index S&P 500 is trading lower by -1.18% from its previous trading close, which means that Biogen Idec stock is outperforming the overall market.
Related Articles
- NASDAQ 100 Round Up - Flat: ATVI, BIIB, FSLR
- NASDAQ 100 Mid-day Update: Flat Top Performers: APOL, ERTS, BIIB
- NASDAQ 100 Mid-day Update: Higher Top Performers: NIHD, BIIB, FSLR
- NASDAQ 100's Top Performers: NFLX, BIIB, MSFT
- NASDAQ 100 Top Performer: Biogen Idec
- NASDAQ 100 Worst Performer: Ctrip.com
- NASDAQ 100 Round Up - Lower: SNDK, BIIB, WCRX
Related Partner Headlines
- Biogen Idec Inc (BIIB): Today's Featured Drugs Winner - TheStreet.com
- Biogen Idec Inc (BIIB): Today's Featured Drugs Winner - TheStreet.com
- Biogen Idec Inc (BIIB): Today's Featured Drugs Winner - TheStreet.com
- Biogen Idec Inc Stock Buy Recommendation Reiterated (BIIB) - TheStreet.com
- Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study - Benzinga
- Biogen Idec Inc Stock Buy Recommendation Reiterated (BIIB) - TheStreet.com
- Biogen Idec Inc (BIIB): Today's Featured Health Care Winner - TheStreet.com
- Biogen Idec Third Quarter Earnings - Investopedia
- Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard - TheStreet.com
- Biogen Idec Inc Stock Buy Recommendation Reiterated (BIIB) - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,294.50 Trade time:4:53PM EDT Value change:0.00 (0.00%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,650.51 Trade time:4:52PM EDT Value change:0.00 (0.00%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,459.42 Trade time:5:15PM EDT Value change:0.00 (0.00%)In The Wires
-
InspireMD To Participate In Benchmark Investor Conference On May 30th -
Red Lion Hotel Anaheim Earns TripAdvisor 2013 Certificate of Excellence, Offers Special Rate -
NetSuite To Showcase Commerce Product Innovation And Customer Success At IRCE 2013 -
rue21, inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition by Funds Advised by Apax Partners -
NetSuite Wins Two SIIA Software CODiE Awards -
Oscar Goodman Will Sign His New Memoir at Hudson News at LAS on Memorial Day -
S&P Capital IQ Initiates Coverage on Tungsten Corp. in Standard & Poor's Factual Stock Reports -
Xumanii™ Announces that it has Entered into Partnership Discussions with Abu Dhabi Media








